Explore the Agenda

8:00 am Check-In & Coffee

8:50 am Chair’s Opening Remarks

Senior Associate Scientist, Stylus Medicine

Driving Quality Through Drug Substance & Raw Material Characterization

9:00 am The Application of Trans-Amplifying RNA in Targeted & Untargeted LNP Systems

Chief Executive Officer & Founder, Amplitude Therapeutics
  • Characterize the unique analytical requirements of trans-amplifying RNA systems, including multi component payload composition, RNA integrity, and encapsulation performance
  • Compare targeted and untargeted LNP approaches to understand how delivery strategy influences cargo behavior and analytical requirements
  • Develop analytical frameworks that connect cargo quality to potency, comparability, and translational readiness

9:30 am LNP Characterization: From pDNA, mRNA & tLNP Purity to In-Process Control

Executive Director, BIA Separations
  • A typical tLNP production process involves mixing nucleic acid(s) with selected lipids, attaching a targeting ligand(s), then purifying and formulating the particles
  • When multiple payloads and multiple ligands are used, tLNP formulations typically yield heterogeneous particles containing more than 90% impurities
  • To better understand these processes and support improved (t)LNP design, new analytical methods and systems have been developed. This presentation will introduce 2D LC switcher analytics
  • The reliability of analytical methods, including the impact of surface effects, will also be discussed

10:00 am Morning Break & Networking

11:00 am Strengthen Targeted LNP Performance Through Advanced Characterization Strategies

Director, Nava Therapeutics
  • Develop quantitative and qualitative assays to accurately characterize targeted LNP composition and surface modifications
  • Assess protein quality, conjugation efficiency, and surface integrity to ensure consistent targeting performance
  • Link analytical characterization to biological function to support robust development, comparability, and translational success

11:30 am Fast & Accurate LNP Analytics: Insights from Spectradyne’s ARC particle analyzer

Application Scientist, Spectradyne LLC
  • Two orthogonal methods in one analysis for comprehensive LNP characterization
  • Quantitative analysis of internal payload, targeting ligand density, size, & concentration
  • The ARC makes accurate nanoparticle analysis fast & easy

11:40 am Systematic Evaluation of RiboGreen-Based Encapsulation Efficiency Measurements for Lipid Nanoparticles

Analytical Advisor, Eli Lilly & Co.
  • Evaluate total and free RNA assays to identify root causes of variability in EE% measurement
  • Identify that nanoparticle-mediated fluorescence attenuation results in free assay imprecision
  • Demonstrate that matrix-matched calibration restores EE% accuracy in both LNP and targeted LNP

12:10 pm Lunch Break & Networking

Next-Generation Multi-Cargo & Complex LNP Systems

1:10 pm Characterizing Targeted LNPs for In Vivo T Cell & Hematopoietic Stem Cell Delivery: Analytical Insights from Discovery Through Translation

Principal Scientist,, Tessera Therapeutics
  • Identify the analytical attributes that influence targeting efficiency and in vivo performance of tLNP systems
  • Explore characterization strategies to assess surface properties, composition, heterogeneity, and structure–function relationships across CAR-T and SCD programs
  • Demonstrate how analytical insights support scale-up, comparability, and translational readiness from discovery through development

1:40 pm Characterize Gene Editing LNPs with Multiple Payloads of Different Sizes

Senior Scientist,, Prime Medicine
  • Measure co-encapsulation efficiency of mRNA and guide RNA, quantify payload ratios, ensure consistent product composition
  • Assess stability of multi-component systems, identify degradation pathways for each cargo, develop orthogonal methods
  • Correlate analytical profiles to editing efficiency, optimize formulations based on data, accelerate development timelines

2:10 pm Overcoming Barriers to T-Cell Delivery with Next-Generation LNPs

Senior Director, Head of Non-Viral Delivery,, Granza Bio
  • Understand the key challenges limiting T-cell targeting and in vivo delivery
  • Explore emerging LNP designs and targeting strategies for improving delivery efficiency
  • Learn how next-generation delivery platforms are enabling new gene editing and immunotherapy applications

2:40 pm Chair’s Closing Remarks

Senior Associate Scientist, Stylus Medicine

3:00 pm End of Conference Day Two